Literature DB >> 17230047

Is there a continuity between bipolar and depressive disorders?

Franco Benazzi1.   

Abstract

BACKGROUND: Recent studies questioned the current categorical split of mood disorders into bipolar disorders (BP) and depressive disorders (MDD).
METHODS: Medline database search of papers from the last 10 years on the categorical-dimensional classification of mood disorders. Various combinations of the following key words were used: mood disorders, bipolar, unipolar, major depressive disorder, spectrum, category/categorical, classification, continuity. Only English language clinical papers were included, review papers were excluded, similar papers selected by quality. The number of papers found was 1,141. The number of papers selected was 109.
RESULTS: The continuity/spectrum between BP (mainly BP-II) and MDD was supported by the following findings:(1) high frequency of mixed states (mixed mania, mixed hypomania, mixed depression, i.e. co-occurring depression and noneuphoric manic/hypomanic symptoms) because opposite polarity symptoms in the same episode do not support a hypomania/mania-depression splitting; (2) MDD was the most common mood disorder in BP probands' relatives; (3) no bimodal distribution of distinguishing symptoms between BP and MDD; (4) bipolar signs not uncommon in MDD; (5) many MDD shifting to BP; (6) many lifetime manic/hypomanic symptoms in MDD; (7) correlation between lifetime manic/hypomanic symptoms and MDD symptoms; (8) hypomania factors in MDD; (9) MDD often recurrent; (10) similar cognitive style. The categorical distinction between BP (mainly BP-I) and MDD was supported by the following findings: (1) BP more common in BP probands' relatives; (2) lower age at BP onset; (3) females as common as males in BP-I, more common than males in MDD; (4) BP-I depression more atypical and retarded, MDD depression more sleepless and agitated; (5) BP more recurrent.
CONCLUSIONS: Focusing on mood spectrum's extremes (BP-I vs. MDD), a categorical distinction seems supported. Focusing on midway disorders (BP-II and MDD plus bipolar signs), a continuity/spectrum seems supported. Results seem to support both a categorical and a dimensional view of mood disorders. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2007        PMID: 17230047     DOI: 10.1159/000097965

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  11 in total

Review 1.  New ways to classify bipolar disorders: going from categorical groups to symptom clusters or dimensions.

Authors:  Chantal Henry; Bruno Etain
Journal:  Curr Psychiatry Rep       Date:  2010-12       Impact factor: 5.285

2.  The mental health clinic: a new model.

Authors:  Giovanni A Fava; Seugn K Park; Steven L Dubovsky
Journal:  World Psychiatry       Date:  2008-10       Impact factor: 49.548

Review 3.  The significance of mixed states in depression and mania.

Authors:  Giulio Perugi; Giuseppe Quaranta; Liliana Dell'Osso
Journal:  Curr Psychiatry Rep       Date:  2014-10       Impact factor: 5.285

4.  Pediatric bipolar disorder versus severe mood dysregulation: risk for manic episodes on follow-up.

Authors:  Argyris Stringaris; Argelinda Baroni; Caroline Haimm; Melissa Brotman; Catherine H Lowe; Frances Myers; Eileen Rustgi; Wanda Wheeler; Reilly Kayser; Kenneth Towbin; Ellen Leibenluft
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2010-04       Impact factor: 8.829

Review 5.  False dogmas in mood disorders research: Towards a nomothetic network approach.

Authors:  Michael Hj Maes; Drozdstoy Stoyanov
Journal:  World J Psychiatry       Date:  2022-05-19

Review 6.  The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression.

Authors:  Michael Maes; Raz Yirmyia; Jens Noraberg; Stefan Brene; Joe Hibbeln; Giulia Perini; Marta Kubera; Petr Bob; Bernard Lerer; Mario Maj
Journal:  Metab Brain Dis       Date:  2008-12-16       Impact factor: 3.584

7.  DNA modification study of major depressive disorder: beyond locus-by-locus comparisons.

Authors:  Gabriel Oh; Sun-Chong Wang; Mrinal Pal; Zheng Fei Chen; Tarang Khare; Mamoru Tochigi; Catherine Ng; Yeqing A Yang; Andrew Kwan; Zachary A Kaminsky; Jonathan Mill; Cerisse Gunasinghe; Jennifer L Tackett; Irving I Gottesman; Gonneke Willemsen; Eco J C de Geus; Jacqueline M Vink; P Eline Slagboom; Naomi R Wray; Andrew C Heath; Grant W Montgomery; Gustavo Turecki; Nicholas G Martin; Dorret I Boomsma; Peter McGuffin; Rafal Kustra; Art Petronis
Journal:  Biol Psychiatry       Date:  2014-07-01       Impact factor: 13.382

8.  Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder.

Authors:  Virginia Soria; Erika Martínez-Amorós; Geòrgia Escaramís; Joaquín Valero; Rosario Pérez-Egea; Cecilia García; Alfonso Gutiérrez-Zotes; Dolors Puigdemont; Mònica Bayés; José M Crespo; Lourdes Martorell; Elisabet Vilella; Antonio Labad; Julio Vallejo; Víctor Pérez; José M Menchón; Xavier Estivill; Mònica Gratacòs; Mikel Urretavizcaya
Journal:  Neuropsychopharmacology       Date:  2010-01-13       Impact factor: 7.853

Review 9.  Bipolar II disorder : epidemiology, diagnosis and management.

Authors:  Franco Benazzi
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 10.  Consensus on nomenclature for clinical staging models in bipolar disorder: A narrative review from the International Society for Bipolar Disorders (ISBD) Staging Task Force.

Authors:  Ralph Kupka; Anne Duffy; Jan Scott; Jorge Almeida; Vicent Balanzá-Martínez; Boris Birmaher; David J Bond; Elisa Brietzke; Ines Chendo; Benicio N Frey; Iria Grande; Danella Hafeman; Tomas Hajek; Manon Hillegers; Marcia Kauer-Sant'Anna; Rodrigo B Mansur; Afra van der Markt; Robert Post; Mauricio Tohen; Hailey Tremain; Gustavo Vazquez; Eduard Vieta; Lakshmi N Yatham; Michael Berk; Martin Alda; Flávio Kapczinski
Journal:  Bipolar Disord       Date:  2021-07-23       Impact factor: 5.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.